参考文献/References:
[1] Mather A,Pollock C.Glucose handling by the kidney[J].Kidney Int Suppl,2011,(120):S1-S6.DOI:10.1038/ki.2010.509.
[2] Girard J.Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2(SGLT2)in diabetes mellitus treatment[J].Nephrol Ther,2017,13(Suppl 1):S35-S41.DOI:10.1016/j.nephro.2017.01.006.
[3] Al-Jobori H,Daniele G,Cersosimo E,et al.Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes[J].Diabetes,2017,66(7):1999-2006.DOI:10.2337/db17-0100.
[4] Iemitsu K,Iizuka T,Takihata M,et al.Factors influencing changes in hemoglobin A1c and body weight during treatment of type 2 diabetes with ipragliflozin: interim analysis of the ASSIGN-K study[J].J Clin Med Res,2016,8(5):373-378.DOI:10.14740/jocmr2492w.
[5] Xiong W,Xiao MY,Zhang M,et al.Efficacy and safety of canagliflozin in patients with type 2 diabetes: a meta-analysis of randomized controlled trials[J].Medicine(Baltimore),2016,95(48):e5473.
[6] Rosenstock J,Chuck L,González-Ortiz M,et al.Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes[J].Diabetes Care,2016,39(3):353-362.DOI:10.2337/dc15-1736.
[7] Cefalu WT,Leiter LA,Yoon KH,et al.Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin(CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial[J].Lancet,2013,382(9896):941-950.DOI:10.1016/S0140-6736(13)60683-2.
[8] Sosale B,Sosale A,Bhattacharyya A. Clinical effectiveness and impact on insulin therapy cost after addition of dapagliflozin to patients with uncontrolled type 2 diabetes[J].Diabetes Ther,2016,7(4):765-776.DOI:10.1007/s13300-016-0204-9.
[9] Frías JP,Guja C,Hardy E,et al.Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy(DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial[J].Lancet Diabetes Endocrinol,2016,4(12):1004-1016.DOI:10.1016/S2213-8587(16)30267-4.
[10] Budoff MJ,Wilding JPH. Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus[J].Int J Clin Pract,2017,71(5).DOI:10.1111/ijcp.12948.
[11] Januzzi JL Jr,Butler J,Jarolim P,et al.Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes[J].J Am Coll Cardiol,2017,70(6):704-712. DOI:10.1016/j.jacc.2017.06.016.
[12] Kosiborod M,Cavender MA,Fu AZ,et al.Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL Study(Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)[J].Circulation,2017,136(3):249-259.DOI:10.1161/CIRCULATIONAHA.117.029190.
[13] Birkeland KI,Jørgensen ME,Carstensen B,et al.Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs(CVD-REAL Nordic): a multinational observational analysis[J].Lancet Diabetes Endocrinol,2017,5(9):709-717.DOI:10.1016/S2213-8587(17)30258-9.
[14] Abdul-Ghani M,Del Prato S,Chilton R,et al.SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study[J].Diabetes Care,2016,39(5):717-725.DOI:10.2337/dc16-0041.
[15] Wanner Ch,Inzucchi SE,Zinman B.Empagliflozin and progression of kidney disease in type 2 diabetes[J].N Engl J Med,2016,375(18):1801-1802.DOI:10.1056/NEJMc1611290.
[16] Cherney DZI,Zinman B,Inzucchi SE,et al.Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial[J].Lancet Diabetes Endocrinol,2017,5(8):610-621.DOI:10.1016/S2213-8587(17)30182-1.
[17] Vallianou NG,Trigkidis K,Kazazis C.Sodium glucose co-transporter 2 inhibitors and their nephroprotective potential[J].Clin Nephrol,2017,87(2017)(4):212-216. DOI:10.5414/CN109013.
[18] Steven S,Oelze M,Hanf A,et al.The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats[J].Redox Biol,2017,13:370-385.DOI:10.1016/j.redox.2017.06.009.
[19] Baker WL,Buckley LF,Kelly MS,et al.Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis[J].J Am Heart Assoc,2017,6(5).pii: e005686.DOI:10.1161/JAHA.117.005686.
[20] Liu XY,Zhang N,Chen R,et al.Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years[J].J Diabetes Complications,2015,29(8):1295-1303. DOI:10.1016/j.jdiacomp.2015.07.011.
[21] Liu J,Li L,Li S,et al.Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis[J].Sci Rep,2017,7(1):2824.DOI:10.1038/s41598-017-02733-w.
[22] FDA Drug Safety Communication. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available from: URI: http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm
[23] Fralick M,Schneeweiss S,Patorno E.Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor[J].N Engl J Med,2017,376(23):2300-2302. DOI:10.1056/NEJMc1701990.
[24] Tang HL,Li DD,Zhang JJ,et al.Lack of evidence for a harmful effect of sodium-glucose co-transporter 2(SGLT2)inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials[J].Diabetes Obes Metab,2016,18(12):1199-1206. DOI:10.1111/dom.12742.
[25] FDA Drug Safety Communication. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin(Invokana, Invokamet, Invokamet XR). Available from: URI: http://www.fda.gov/Drugs/DrugSafety/ucm557507.htm
[26] Nadkarni GN,Ferrandino R,Chang A,et al.Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis[J].Diabetes Care,2017,40(11):1479-1485.DOI:10.2337/dc17-1011.
[27] Ptaszynska A,Cohen SM,Messing EM,et al.Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study'[J].Diabetes Ther,2015,6(3):357-375. DOI:10.1007/s13300-015-0128-9.
相似文献/References:
[1]赵紫琴,雒瑢,田凤石,等.替米沙坦对OLETF大鼠皮下和内脏脂肪组织PPARγ表达的影响[J].国际内分泌代谢杂志,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
Zhao Ziqin*,Luo Rong,Tian Fengshi,et al.Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats[J].International Journal of Endocrinology and Metabolism,2014,(03):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
[2]姚霜霜,张翼飞,张志国,等.小檗碱改善代谢性疾病的肠道相关机制[J].国际内分泌代谢杂志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(03):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[3]曹萌 韦晓 刘超.自噬与胰岛β细胞功能及2型糖尿病[J].国际内分泌代谢杂志,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
Cao Meng,Wei Xiao,Liu Chao..Relationship between autophagy and islet β cells function, type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(03):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
[4]刘艳 田秀标 韩颖.GLP-1受体激动剂呈葡萄糖依赖性刺激胰岛β细胞胰岛素分泌的机制[J].国际内分泌代谢杂志,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
Liu Yan*,Tian Xiubiao,Han Ying..Mechanism of GLP-1 receptor agonists in the stimulation of insulin secretion of islet β cell in a glucose-dependent manner[J].International Journal of Endocrinology and Metabolism,2015,(03):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
[5]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(03):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[6]梅稳,向光大,卢俊颜,等.GDF11对ApoE-/-糖尿病小鼠内皮依赖性
血管舒张功能的作用[J].国际内分泌代谢杂志,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
Mei Wen*,Xiang Guangda,Lu Junyan,et al.Effects of GDF11 on endothelium-dependent vasodiation function of aorta in ApoE-/- diabetic mice[J].International Journal of Endocrinology and Metabolism,2016,36(03):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
[7]殷俏,张云良,郭淑芹,等.视黄醇结合蛋白4、超敏C反应蛋白
与糖尿病视网膜病变的关系[J].国际内分泌代谢杂志,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
Yin Qiao,Zhang Yunliang,Guo Shuqin,et al.Relationship of retinol binding protein 4 and high sensitive C-reactive protein with diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
[8]王涛,张洁,祁范范,等.不同糖耐量人群血清25(OH)D3水平
及与胰岛β细胞功能的关系[J].国际内分泌代谢杂志,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
Wang Tao*,Zhang Jie,Qi Fanfan,et al.Relationship between serum 25(OH)D3 level and islet β cell function in individuals with different glucose tolerance[J].International Journal of Endocrinology and Metabolism,2016,36(03):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
[9]陈双双,王楚媛,孔令芳.铬与2型糖尿病[J].国际内分泌代谢杂志,2016,36(04):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
Chen Shuangshuang,Wang Chuyuan,Kong Lingfang.Chromium and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2016,36(03):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
[10]涂萍,许婷,段鹏,等.25-羟维生素D3补充对绝经后2型糖尿病
患者胰岛素敏感性及血糖控制的影响[J].国际内分泌代谢杂志,2016,36(05):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]
Tu Ping,Xu Ting,Duan Peng,et al.Influence of 25-hydroxyvitamin D3 supplement on insulin sensitivity and glucose control in postmenopausal patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(03):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]